# Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

> **NCT03208218** · PHASE1 · COMPLETED · sponsor: **Samyang Biopharmaceuticals Corporation** · enrollment: 42 (actual)

## Conditions studied

- Healthy, Male

## Interventions

- **DRUG:** SYP-1512
- **DRUG:** Revlimid cap

## Key facts

- **NCT ID:** NCT03208218
- **Lead sponsor:** Samyang Biopharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-17
- **Primary completion:** 2016-08-25
- **Final completion:** 2016-10-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2017-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208218, "Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03208218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*